b infantis evc001  (Evolve BioSystems Inc)

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: Model schematic. ( A ) Timeline for dosing optimization trials with Lacto-N-Tetraose (LNT) and EVC001. ( B ) Timeline for the Paneth cell disruption with bacterial dysbiosis NEC model as well as the incorporation of the dosing scheme for LNT and EVC001. ( C ) Timeline for the RMS NEC model with the incorporation of EVC001 dosing. RMS, Rodent Milk Substitute.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Disruption

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: MCT oil in human-relevant doses is toxic to mice and must be tailored to size. ( A ) NEC injury scores for mice receiving MCT oil with or without gavage of LNT ( n ≥ 4 mice per group). ( B ) Serum cytokine analysis for IL-10, IL-6, KC-GRO, and TNF for mice given MCT oil with or without gavage of LNT ( n ≥ 4 mice per group). ( C ) Cecal microbiome analysis of the phylum-level relative abundances for mice given MCT oil with or without gavage of LNT ( n ≥ 4 mice per group). ( D ) NEC injury scores for mice receiving varying doses of probiotic EVC001 ( n ≥ 4 mice per group). ( E ) Serum cytokine analysis for mice receiving varying doses of EVC001 ( n ≥ 4 mice per group). ( F ) Cecal microbiome analysis of the phylum-level relative abundances for mice given varying doses of EVC001 ( n ≥ 4 mice per group). ( G ) Cecal microbiome Bifidobacteriaceae family level relative abundances for mice given varying doses of EVC001 ( n ≥ 4 mice per group). For all p values, * ≤ 0.05, ** ≤ 0.01.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques:

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: EVC001 decreases experimental NEC injury scores in the Paneth cell disruption with bacterial dysbiosis model. ( A ) NEC injury scores for control mice, NEC mice, and NEC mice receiving LNT (HNEC), without LNT, but with EVC001 (EvNEC) or with LNT and EVC001 (EvHNEC) ( n ≥ 3 mice per group). ( B ) Quantitative PCR probing for B. infantis within the cecal and fecal microbiome ( n ≥ 3 mice per group). ( C ) Serum cytokine levels for IL-10, IL-6, KC-GRO, and TNF and the representative fold changes. ( D ) Phylum level relative abundances for the cecal microbiome ( n ≥ 6 mice per group). ( E ) Enterobacteriaceae family level relative abundances for the cecal microbiome ( n ≥ 6 mice per group). ( F ) Bifidobacteriaceae family level relative abundances for the cecal microbiome (n ≥ 6 mice per group). ( G ) Phylum level relative abundances for the fecal microbiome (colon contents) ( n ≥ 6 mice per group). ( H ) Enterobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 6 mice per group). ( I ) Bifidobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 6 mice per group). ( J ) Weighted UniFrac principal coordinate analysis plot including cecal and fecal samples within each group ( n ≥ 6 mice per group). For all p values, * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Disruption, Control, Real-time Polymerase Chain Reaction

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: EVC001 efficacy in decreasing experimental NEC injury is model dependent. ( A ) NEC injury scores for control mice, RMS formula NEC mice, and RMS formula NEC mice receiving EVC001 (Ev RMS NEC) ( n ≥ 5 mice per group) ( B ) Serum cytokine levels for IL-10, IL-6, KC-GRO, and TNF and the representative fold changes ( C ) Quantitative PCR probing for B. infantis EVC001 DNA within the cecal and fecal microbiome ( n ≥ 5 mice per group) ( D ) Phylum level relative abundances for the cecal microbiome ( n ≥ 5 mice per group) ( E ) Bifidobacteriaceae family level relative abundances for the cecal microbiome ( n ≥ 5 mice per group) ( F ) Phylum level relative abundances for the fecal microbiome (colon contents) ( n ≥ 5 mice per group) ( G ) Bifidobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 5 mice per group) ( H ) Weighted UniFrac principal coordinate analysis plot including cecal and fecal samples within each group ( n ≥ 5 mice per group). For all p values, * ≤ 0.05, ** * ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Control, Real-time Polymerase Chain Reaction

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: Wound healing assay results show B. infantis EVC001 metabolites can improve intestinal epithelial cell wound healing. ( A ) Compared wound healing results between sham and RPMI and results from the wound healing assay ( n ≥ 3 wounds per group) ( B ) Representative microscopy images of the epithelial cells with the original wound size at the 0-h time point (solid line) added for comparison to the degree of healing at the 12-h time point (dashed line). For all p values, * ≤ 0.05, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Wound Healing Assay, Microscopy, Comparison

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: EVC001 decreases experimental NEC injury scores in the Paneth cell disruption with bacterial dysbiosis model. ( A ) NEC injury scores for control mice, NEC mice, and NEC mice receiving LNT (HNEC), without LNT, but with EVC001 (EvNEC) or with LNT and EVC001 (EvHNEC) ( n ≥ 3 mice per group). ( B ) Quantitative PCR probing for B. infantis within the cecal and fecal microbiome ( n ≥ 3 mice per group). ( C ) Serum cytokine levels for IL-10, IL-6, KC-GRO, and TNF and the representative fold changes. ( D ) Phylum level relative abundances for the cecal microbiome ( n ≥ 6 mice per group). ( E ) Enterobacteriaceae family level relative abundances for the cecal microbiome ( n ≥ 6 mice per group). ( F ) Bifidobacteriaceae family level relative abundances for the cecal microbiome (n ≥ 6 mice per group). ( G ) Phylum level relative abundances for the fecal microbiome (colon contents) ( n ≥ 6 mice per group). ( H ) Enterobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 6 mice per group). ( I ) Bifidobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 6 mice per group). ( J ) Weighted UniFrac principal coordinate analysis plot including cecal and fecal samples within each group ( n ≥ 6 mice per group). For all p values, * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Mice in the probiotic or probiotic control groups were given 200 μL of the HMO, LNT (Jennewein Biotechnologie GmbH, Rheinbreitbach, Germany)/water and 100 μL MCT oil/EVC001 as seen in B. Bifidobacterium longum subspecies infantis ( B. infantis) was provided by Evolve Biosystems (Davis, CA, USA) at a concentration of 8 billion CFU/0.5 mL already prepared in MCT oil suspension and kept at −20 °C until ready to utilize [ ].

Techniques: Disruption, Control, Real-time Polymerase Chain Reaction

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: EVC001 efficacy in decreasing experimental NEC injury is model dependent. ( A ) NEC injury scores for control mice, RMS formula NEC mice, and RMS formula NEC mice receiving EVC001 (Ev RMS NEC) ( n ≥ 5 mice per group) ( B ) Serum cytokine levels for IL-10, IL-6, KC-GRO, and TNF and the representative fold changes ( C ) Quantitative PCR probing for B. infantis EVC001 DNA within the cecal and fecal microbiome ( n ≥ 5 mice per group) ( D ) Phylum level relative abundances for the cecal microbiome ( n ≥ 5 mice per group) ( E ) Bifidobacteriaceae family level relative abundances for the cecal microbiome ( n ≥ 5 mice per group) ( F ) Phylum level relative abundances for the fecal microbiome (colon contents) ( n ≥ 5 mice per group) ( G ) Bifidobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 5 mice per group) ( H ) Weighted UniFrac principal coordinate analysis plot including cecal and fecal samples within each group ( n ≥ 5 mice per group). For all p values, * ≤ 0.05, ** * ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Mice in the probiotic or probiotic control groups were given 200 μL of the HMO, LNT (Jennewein Biotechnologie GmbH, Rheinbreitbach, Germany)/water and 100 μL MCT oil/EVC001 as seen in B. Bifidobacterium longum subspecies infantis ( B. infantis) was provided by Evolve Biosystems (Davis, CA, USA) at a concentration of 8 billion CFU/0.5 mL already prepared in MCT oil suspension and kept at −20 °C until ready to utilize [ ].

Techniques: Control, Real-time Polymerase Chain Reaction

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: Wound healing assay results show B. infantis EVC001 metabolites can improve intestinal epithelial cell wound healing. ( A ) Compared wound healing results between sham and RPMI and results from the wound healing assay ( n ≥ 3 wounds per group) ( B ) Representative microscopy images of the epithelial cells with the original wound size at the 0-h time point (solid line) added for comparison to the degree of healing at the 12-h time point (dashed line). For all p values, * ≤ 0.05, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Mice in the probiotic or probiotic control groups were given 200 μL of the HMO, LNT (Jennewein Biotechnologie GmbH, Rheinbreitbach, Germany)/water and 100 μL MCT oil/EVC001 as seen in B. Bifidobacterium longum subspecies infantis ( B. infantis) was provided by Evolve Biosystems (Davis, CA, USA) at a concentration of 8 billion CFU/0.5 mL already prepared in MCT oil suspension and kept at −20 °C until ready to utilize [ ].

Techniques: Wound Healing Assay, Microscopy, Comparison

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: Model schematic. ( A ) Timeline for dosing optimization trials with Lacto-N-Tetraose (LNT) and EVC001. ( B ) Timeline for the Paneth cell disruption with bacterial dysbiosis NEC model as well as the incorporation of the dosing scheme for LNT and EVC001. ( C ) Timeline for the RMS NEC model with the incorporation of EVC001 dosing. RMS, Rodent Milk Substitute.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Disruption

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: MCT oil in human-relevant doses is toxic to mice and must be tailored to size. ( A ) NEC injury scores for mice receiving MCT oil with or without gavage of LNT ( n ≥ 4 mice per group). ( B ) Serum cytokine analysis for IL-10, IL-6, KC-GRO, and TNF for mice given MCT oil with or without gavage of LNT ( n ≥ 4 mice per group). ( C ) Cecal microbiome analysis of the phylum-level relative abundances for mice given MCT oil with or without gavage of LNT ( n ≥ 4 mice per group). ( D ) NEC injury scores for mice receiving varying doses of probiotic EVC001 ( n ≥ 4 mice per group). ( E ) Serum cytokine analysis for mice receiving varying doses of EVC001 ( n ≥ 4 mice per group). ( F ) Cecal microbiome analysis of the phylum-level relative abundances for mice given varying doses of EVC001 ( n ≥ 4 mice per group). ( G ) Cecal microbiome Bifidobacteriaceae family level relative abundances for mice given varying doses of EVC001 ( n ≥ 4 mice per group). For all p values, * ≤ 0.05, ** ≤ 0.01.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques:

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: EVC001 decreases experimental NEC injury scores in the Paneth cell disruption with bacterial dysbiosis model. ( A ) NEC injury scores for control mice, NEC mice, and NEC mice receiving LNT (HNEC), without LNT, but with EVC001 (EvNEC) or with LNT and EVC001 (EvHNEC) ( n ≥ 3 mice per group). ( B ) Quantitative PCR probing for B. infantis within the cecal and fecal microbiome ( n ≥ 3 mice per group). ( C ) Serum cytokine levels for IL-10, IL-6, KC-GRO, and TNF and the representative fold changes. ( D ) Phylum level relative abundances for the cecal microbiome ( n ≥ 6 mice per group). ( E ) Enterobacteriaceae family level relative abundances for the cecal microbiome ( n ≥ 6 mice per group). ( F ) Bifidobacteriaceae family level relative abundances for the cecal microbiome (n ≥ 6 mice per group). ( G ) Phylum level relative abundances for the fecal microbiome (colon contents) ( n ≥ 6 mice per group). ( H ) Enterobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 6 mice per group). ( I ) Bifidobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 6 mice per group). ( J ) Weighted UniFrac principal coordinate analysis plot including cecal and fecal samples within each group ( n ≥ 6 mice per group). For all p values, * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Disruption, Control, Real-time Polymerase Chain Reaction

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: EVC001 efficacy in decreasing experimental NEC injury is model dependent. ( A ) NEC injury scores for control mice, RMS formula NEC mice, and RMS formula NEC mice receiving EVC001 (Ev RMS NEC) ( n ≥ 5 mice per group) ( B ) Serum cytokine levels for IL-10, IL-6, KC-GRO, and TNF and the representative fold changes ( C ) Quantitative PCR probing for B. infantis EVC001 DNA within the cecal and fecal microbiome ( n ≥ 5 mice per group) ( D ) Phylum level relative abundances for the cecal microbiome ( n ≥ 5 mice per group) ( E ) Bifidobacteriaceae family level relative abundances for the cecal microbiome ( n ≥ 5 mice per group) ( F ) Phylum level relative abundances for the fecal microbiome (colon contents) ( n ≥ 5 mice per group) ( G ) Bifidobacteriaceae family level relative abundances for the fecal microbiome ( n ≥ 5 mice per group) ( H ) Weighted UniFrac principal coordinate analysis plot including cecal and fecal samples within each group ( n ≥ 5 mice per group). For all p values, * ≤ 0.05, ** * ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Control, Real-time Polymerase Chain Reaction

Journal: Nutrients

Article Title: Bifidobacterium longum Subspecies infantis Strain EVC001 Decreases Neonatal Murine Necrotizing Enterocolitis

doi: 10.3390/nu14030495

Figure Lengend Snippet: Wound healing assay results show B. infantis EVC001 metabolites can improve intestinal epithelial cell wound healing. ( A ) Compared wound healing results between sham and RPMI and results from the wound healing assay ( n ≥ 3 wounds per group) ( B ) Representative microscopy images of the epithelial cells with the original wound size at the 0-h time point (solid line) added for comparison to the degree of healing at the 12-h time point (dashed line). For all p values, * ≤ 0.05, *** ≤ 0.001, and **** ≤ 0.0001.

Article Snippet: Cells were then starved in DMEM with 0.5% fetal bovine serum, with 100 U/L penicillin G and 100 U/L streptomycin C. Culture medium supernatant from B. infantis EVC001 grown in RPMI 1640 medium (Thermofisher, Waltham, MA, USA) plus 2% glucose for 16 hours (Evolve BioSystems, Davis, CA, USA) was then added at 1 and 10% dilutions.

Techniques: Wound Healing Assay, Microscopy, Comparison

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: (A) Inclusion and inclusion criteria for participation in the study. (B) Fecal samples collected over time, arranged by Study ID (y-axis) and corrected gestational age (x-axis). Group assignment is denoted by a teal (EVC001) or gray box (control). The data points are shaded by the abundance of human milk an infant was receiving at sample collection and shapes represent study day for sample collection (see legend). Colored vertical lines represent interval periods for sample collection at targeted gestational age (+/- 3 days).

Article Snippet: Infants enrolled in the EVC001 group received a daily feeding of 8.0 x 10 9 CFU of activated B. infantis EVC001 (commercially available as Evivo® in MCT oil, Evolve BioSystems, Inc.) initiated by day 10 of life and continued until hospital discharge.

Techniques: Control

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: Subject Characteristics.

Article Snippet: Infants enrolled in the EVC001 group received a daily feeding of 8.0 x 10 9 CFU of activated B. infantis EVC001 (commercially available as Evivo® in MCT oil, Evolve BioSystems, Inc.) initiated by day 10 of life and continued until hospital discharge.

Techniques:

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: Safety and Tolerability.

Article Snippet: Infants enrolled in the EVC001 group received a daily feeding of 8.0 x 10 9 CFU of activated B. infantis EVC001 (commercially available as Evivo® in MCT oil, Evolve BioSystems, Inc.) initiated by day 10 of life and continued until hospital discharge.

Techniques: Infection, Disruption, Reflux

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: Discharge Summary.

Article Snippet: Infants enrolled in the EVC001 group received a daily feeding of 8.0 x 10 9 CFU of activated B. infantis EVC001 (commercially available as Evivo® in MCT oil, Evolve BioSystems, Inc.) initiated by day 10 of life and continued until hospital discharge.

Techniques: Control, Infant Formula

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: (A) Absolute quantification of B. infantis by qPCR. The data are represented as Log10 CFU per μg of genomic DNA extracted from swab stool samples. Data in boxplots show the median, first, and third quartiles. Statistical differences determined by Wilcoxon Rank Sum test. (B) Negative correlation (Spearman's) between the abundance of Bifidobacteriaceae and Enterobacteriaceae families in infants in the EVC001 group. Data points for baseline were excluded from the correlation analysis. All P -values are FDR-corrected.

Article Snippet: Infants enrolled in the EVC001 group received a daily feeding of 8.0 x 10 9 CFU of activated B. infantis EVC001 (commercially available as Evivo® in MCT oil, Evolve BioSystems, Inc.) initiated by day 10 of life and continued until hospital discharge.

Techniques: Quantitative Proteomics

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: For all panels, all available samples were analyzed from Study Day 14 [ n = 13 control, n = 12 EVC001]. (A) Heatmap showing the relative abundance of HMO-utilization genes in the fecal metagenomes of preterm infants in the control (gray boxes) and EVC001 (teal boxes) groups. As denoted, rows represent genes within in the urease operon, a 43-kb cluster associated with utilization of human milk oligosaccharides (H-1), putative fucose utilization regions (H-2 and H-3), putative sialic acid utilization region (H-4) and LNB metabolism gene region (H-5). (B) Average and standard error of volume of human milk consumed by infants in the control and EVC001 groups. Individual data points are represented. ns, not significant. (C) Absolute abundance and standard error of HMOs in the fecal samples. Statistical differences determined with Wilcoxon Rank Sum test. (D) Spearman's correlation between abundance of HMOs and the absolute abundance (Log10 CFU) of B. infantis in the fecal samples. Data points represent individual infants and are colored by group.

Article Snippet: Infants enrolled in the EVC001 group received a daily feeding of 8.0 x 10 9 CFU of activated B. infantis EVC001 (commercially available as Evivo® in MCT oil, Evolve BioSystems, Inc.) initiated by day 10 of life and continued until hospital discharge.

Techniques: Control

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: (A) Inclusion and inclusion criteria for participation in the study. (B) Fecal samples collected over time, arranged by Study ID (y-axis) and corrected gestational age (x-axis). Group assignment is denoted by a teal (EVC001) or gray box (control). The data points are shaded by the abundance of human milk an infant was receiving at sample collection and shapes represent study day for sample collection (see legend). Colored vertical lines represent interval periods for sample collection at targeted gestational age (+/- 3 days).

Article Snippet: Although B. infantis EVC001 has been previously fed to preterm infants with no adverse effects , this open-label study aimed specifically to prospectively evaluate the safety and tolerability of B. infantis EVC001 and its effects on the fecal microbiota in at-risk, hospitalized preterm infants (<33 weeks gestational age at birth or <1,500 g birth weight) in the NICU at Orlando Health Winnie Palmer Hospital.

Techniques: Control

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: Subject Characteristics.

Article Snippet: Although B. infantis EVC001 has been previously fed to preterm infants with no adverse effects , this open-label study aimed specifically to prospectively evaluate the safety and tolerability of B. infantis EVC001 and its effects on the fecal microbiota in at-risk, hospitalized preterm infants (<33 weeks gestational age at birth or <1,500 g birth weight) in the NICU at Orlando Health Winnie Palmer Hospital.

Techniques:

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: Safety and Tolerability.

Article Snippet: Although B. infantis EVC001 has been previously fed to preterm infants with no adverse effects , this open-label study aimed specifically to prospectively evaluate the safety and tolerability of B. infantis EVC001 and its effects on the fecal microbiota in at-risk, hospitalized preterm infants (<33 weeks gestational age at birth or <1,500 g birth weight) in the NICU at Orlando Health Winnie Palmer Hospital.

Techniques: Infection, Disruption, Reflux

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: Discharge Summary.

Article Snippet: Although B. infantis EVC001 has been previously fed to preterm infants with no adverse effects , this open-label study aimed specifically to prospectively evaluate the safety and tolerability of B. infantis EVC001 and its effects on the fecal microbiota in at-risk, hospitalized preterm infants (<33 weeks gestational age at birth or <1,500 g birth weight) in the NICU at Orlando Health Winnie Palmer Hospital.

Techniques: Control, Infant Formula

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: (A) Absolute quantification of B. infantis by qPCR. The data are represented as Log10 CFU per μg of genomic DNA extracted from swab stool samples. Data in boxplots show the median, first, and third quartiles. Statistical differences determined by Wilcoxon Rank Sum test. (B) Negative correlation (Spearman's) between the abundance of Bifidobacteriaceae and Enterobacteriaceae families in infants in the EVC001 group. Data points for baseline were excluded from the correlation analysis. All P -values are FDR-corrected.

Article Snippet: Although B. infantis EVC001 has been previously fed to preterm infants with no adverse effects , this open-label study aimed specifically to prospectively evaluate the safety and tolerability of B. infantis EVC001 and its effects on the fecal microbiota in at-risk, hospitalized preterm infants (<33 weeks gestational age at birth or <1,500 g birth weight) in the NICU at Orlando Health Winnie Palmer Hospital.

Techniques: Quantitative Proteomics

Journal: Frontiers in Pediatrics

Article Title: B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

doi: 10.3389/fped.2021.795970

Figure Lengend Snippet: For all panels, all available samples were analyzed from Study Day 14 [ n = 13 control, n = 12 EVC001]. (A) Heatmap showing the relative abundance of HMO-utilization genes in the fecal metagenomes of preterm infants in the control (gray boxes) and EVC001 (teal boxes) groups. As denoted, rows represent genes within in the urease operon, a 43-kb cluster associated with utilization of human milk oligosaccharides (H-1), putative fucose utilization regions (H-2 and H-3), putative sialic acid utilization region (H-4) and LNB metabolism gene region (H-5). (B) Average and standard error of volume of human milk consumed by infants in the control and EVC001 groups. Individual data points are represented. ns, not significant. (C) Absolute abundance and standard error of HMOs in the fecal samples. Statistical differences determined with Wilcoxon Rank Sum test. (D) Spearman's correlation between abundance of HMOs and the absolute abundance (Log10 CFU) of B. infantis in the fecal samples. Data points represent individual infants and are colored by group.

Article Snippet: Although B. infantis EVC001 has been previously fed to preterm infants with no adverse effects , this open-label study aimed specifically to prospectively evaluate the safety and tolerability of B. infantis EVC001 and its effects on the fecal microbiota in at-risk, hospitalized preterm infants (<33 weeks gestational age at birth or <1,500 g birth weight) in the NICU at Orlando Health Winnie Palmer Hospital.

Techniques: Control